Galectin Therapeutics stock looks like a compelling swing long setup on the chart. The gambit is a bounce off its 200 day moving average support.
Galectin Therapeutics has no Sell ratings, 1 Hold rating, and 3 Buy ratings. The average target price is $5.25 which represents 93% upside from the current price.
Galectin is scheduled to report Phase 2b top-line data within the next week or two for GR-MD-02 non-alcoholic steatohepatitis (NASH) with cirrhosis.
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. You can read more about the company on their website.
Galectin Therapeutics Stock
You can see the technical trade on the chart. We have a short-term swing move higher likely coming soon. Galectin Therapeutics stock has repeatedly swung higher off current support. The Twiggs Money Flow seems ready to break positive.
Galectin Therapeutics presents a decent setup pattern. Prices have been consolidating lately. There is a very little resistance above the current price.
Latest posts by Lance Jepsen
- Itau Unibanco Stock For An Improving Brazil Economy - December 13, 2017
- Comtech Telecommunications Stock Does Candle Over Candle Off Trend Line - December 13, 2017
- Top News Stories For December 12 2017 - December 12, 2017